Comparative Study of the Antibacterial Activity of Selected Ciprofloxacin Tablet Brands Available in Iraq
Ensuring the microbiological quality of antibiotics is essential for effective treatment and resistance prevention. In Iraq, several ciprofloxacin tablet brands are commercially available, yet limited data exist on their in vitro antibacterial potency. This study compared five ciprofloxacin brands from Switzerland, Germany, Iraq, Jordan, and Turkey. Antibacterial activity was assessed using disk diffusion, broth microdilution for Minimum Inhibitory Concentration (MIC), and time-kill kinetics assays, following CLSI standards. Significant differences in antibacterial activity were observed. Brand A (Switzerland) and brand B (Germany) showed the largest inhibition zones (35.7 mm and 34.3 mm for Escherichia coli) and the lowest MICs (0.008 μg/mL for E. coli, 0.25 μg/mL for Pseudomonas aeruginosa, and 0.125 μg/mL for Staphylococcus aureus), matching the reference standard. Brand E (Turkey) had the smallest zones (30.7 mm) and the highest MICs (0.031-1.0 μg/mL). In time-kill assays, brands A and B achieved 3-log bacterial reduction within 4-6 hours, while brands C, D, and E required 6-10 h. Correlation analysis revealed strong relationships between antibacterial performance and price (r = 0.896, p = 0.016) and tablet hardness (r = 0.782, p = 0.038), while disintegration time and weight variation showed no significant impact. Major Findings: Swiss and German ciprofloxacin brands demonstrated superior antibacterial efficacy, reflected in larger inhibition zones, lower MICs, and faster killing rates. These findings emphasise the need for mandatory microbiological quality testing of antibiotics marketed in Iraq.